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The medium chain triglyceride ketogenic diet is an established treatment for drug-resistant epilepsy that increases plasma levels of
decanoic acid and ketones. Recently, decanoic acid has been shown to provide seizure control in vivo, yet its mechanism of action
remains unclear. Here we show that decanoic acid, but not the ketones b-hydroxybutryate or acetone, shows antiseizure activity in two
acute ex vivo rat hippocampal slice models of epileptiform activity. To search for a mechanism of decanoic acid, we show it has a
strong inhibitory effect on excitatory, but not inhibitory, neurotransmission in hippocampal slices. Using heterologous expression of
excitatory ionotropic glutamate receptor AMPA subunits in Xenopus oocytes, we show that this effect is through direct AMPA receptor
inhibition, a target shared by a recently introduced epilepsy treatment perampanel. Decanoic acid acts as a non-competitive antagonist
at therapeutically relevant concentrations, in a voltage- and subunit-dependent manner, and this is sufﬁcient to explain its antiseizure
effects. This inhibitory effect is likely to be caused by binding to sites on the M3 helix of the AMPA-GluA2 transmembrane domain;
independent from the binding site of perampanel. Together our results indicate that the direct inhibition of excitatory neurotransmission
by decanoic acid in the brain contributes to the anti-convulsant effect of the medium chain triglyceride ketogenic diet.
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Introduction
The medium chain triglyceride (MCT) ketogenic diet was ﬁrst
identiﬁed as a treatment for refractory epilepsy in 1971
(Huttenlocher et al., 1971). It has provided one of the
most effective therapeutic approaches for children with
drug-resistant epilepsy (Liu, 2008; Neal and Cross, 2010;
Levy et al., 2012) and has recently been demonstrated to
be effective in childhood epilepsy in a randomized control
trial (Neal et al., 2009). However, the diet has adverse
gastro-intestinal related side effects, such as diarrhoea, vomit-
ing, bloating, and cramps (Liu, 2008). Furthermore, it has
also been shown that there is a high attrition rate for the diet,
due to many patients ﬁnding the diet difﬁcult to tolerate
(Levy et al., 2012). An understanding of the mechanism of
action of the diet will not only provide insight into mechan-
isms underlying epilepsy, but also facilitate the development
of novel drugs and better targeted dietary therapies that are
effective in drug-resistant epilepsy, yet lack many of the
adverse effects of the conventional MCT diet.
Understanding the therapeutic mechanism of the diet has
been challenging (Rho and Sankar, 2008; Rho and
Stafstrom, 2011). It was initially assumed that ketone produc-
tion was the key to the diet’s antiepileptic effect, but there is a
poor correlation between serum ketones and seizure control
(Likhodii et al., 2000; Thavendiranathan et al., 2000).
Moreover, in vitro and in vivo studies of the anticonvulsant
effects of ketones have proved inconclusive (Likhodii et al.,
2000; Thavendiranathan et al., 2000). In addition to ketones,
the diet also causes an increase in plasma levels of the two
fatty acids provided in MCT oil, the straight chain, 10-carbon
decanoic acid, and the eight-carbon octanoic acid
(Haidukewych et al., 1982; Sills et al., 1986a). Recently, it
has been established that decanoic acid has antiseizure effects
at clinically relevant concentrations in vitro and in vivo (Chang
et al., 2013; Wlaz et al., 2015) but octanoic acid does not, and
with previous in vivo pharmacokinetic data indicating that
decanoic acid penetrates the blood–brain barrier (Oldendorf,
1973), these data suggest that decanoic acid directly contri-
butes to the therapeutic effect of the MCT ketogenic diet.
Indeed, in vitro, decanoic acid is more potent than valproic
acid [a branched chain fatty acid isomer of octanoic acid, that
is commonly used in the treatment of epilepsy (Chang et al.,
2013), and which has been shown to act on phosphoinositide
signalling in seizure control (Xu et al., 2007; Chang et al.,
2012, 2014a)]. Thus, it is unclear if ketones or decanoic
acid provide direct, acute antiseizure effects during administra-
tion of an MCT diet, and by what mechanism. These ques-
tions are addressed here.
Materials and methods
Animals
Male Sprague-Dawley rats were housed in cages under con-
trolled environmental conditions (24–25C; 50–60% humidity;
12-h light/dark cycle) with free access to food and water. All
efforts were made to minimize the number of animals used. All
experiments were performed under personal and project li-
censes approved by the Home Ofﬁce, London, UK under regu-
lations of the UK Animal (Scientiﬁc Procedures) Act, 1986.
Slice preparation
Male Sprague-Dawley rats (postnatal Days 19–30) were sacri-
ﬁced using an overdose of isoﬂurane or pentobarbitone
(500mg/kg). After decapitation the brain was rapidly removed,
the hippocampus or entorhinal cortex-hippocampus slices
was dissected from the brain and 350-mM thick transverse
slices were prepared on a VT1200S vibratome (Leica) or
Vibratome (Vibratome 1500 sectioning system, Intracell).
The slicing was performed in ice-cold sucrose-based solution
containing (in mM): 75 sucrose, 87 NaCl, 22 glucose, 2.5 KCl,
7 MgCl2, 1.25 NaH2PO4, 0.5 CaCl2 and 25 NaHCO3, pH
7.4, 315–330 mOsm equilibrated with 95% O2 plus 5% CO2.
The slices were then stored in a continuously oxygenated
humidiﬁed interface holding chamber containing oxygenated
artiﬁcial CSF (in mM): 120 NaCl, 22 glucose, 2.5 KCl, 1.3
MgSO4, 1 NaH2PO4, 25 NaHCO3 and 2.5 CaCl2, pH 7.4 296
mOsm, where they recovered for at least 1 h before use.
Electrophysiology
In vitro seizure model
During the experiment, slices were transferred from the interface
chamber into a submerged recording chamber, designed to op-
timize wash-in and wash-out of drugs, and continuously per-
fused using gravity feed at 3–6ml/min with prewarmed (36C)
oxygenated artiﬁcial CSF (95% O2, 5% CO2). Field potentials
were recorded with a glass microelectrode (1–2M) ﬁlled with
artiﬁcial CSF solution placed in stratum radiatum of CA1 and
were ﬁltered at 1 kHz and digitized at 2 kHz (using an npi EXT-
02F extracellular ampliﬁer recorded with WinEDR software). In
the pentylenetetrazol model, the epileptiform (paroxysmal) ac-
tivity was induced by application of pentylenetetrazol (2mM) to
the perfusate and [K+] was increased (to 6mM); in low-Mg2+
model, the epileptiform activity was elicited by using Mg2+-free
artiﬁcial CSF. Once the frequency of the paroxysmal activity
was stable for at least 10 min, compounds were applied to
the perfusate for the following 40min, and washed out for a
remaining 20min. The anticonvulsant effects were evaluated by
measuring the change in the frequency of the discharges at
minute intervals. The discharge frequency was then averaged
every 5 min during the experiment and normalized to baseline.
The compounds applied in this study included: 1% dimethyl
sulphoxide (DMSO), acetone (10mM, Sigma), ( )-sodium
3-hydroxybutyrate (BHB) (10mM, Sigma), and decanoic
acid (1mM, Alfa Aesar Pty). Acetone and decanoic acids were
prepared as 1000 stocks in DMSO, and BHB was prepared
as 100 stock. Stocks were dissolved in artiﬁcial CSF to
achieve their ﬁnal concentrations during experiments, and
where applicable, experiments included constant levels of
DMSO.
Whole-cell patch clamp
For electrophysiological recording, the slices were placed in a
recording chamber constantly perfused with 32–34C
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oxygenated artiﬁcial CSF solution using a gravity-driven
perfusion system. Whole-cell patch clamp recordings were
performed on CA1 pyramidal cells (input resistance
330  70MV) visualized using an infrared differential contrast
imaging system. For patching, standard walled borosilicate
glass pipettes with a resistance of 2.5–3.5MV were used,
ﬁlled with an intracellular pipette solution containing
(in mM): 120 Cs-methanesulphonate, 10 HEPES, 0.2 EGTA,
8 NaCl, 0.2 MgCl2, 2Mg-ATP, 0.3Na-GTP, 5 QX314-Br, 10
phosphocreatine, pH adjusted to 7.2 and osmolality adjusted
to 296 mOsm. Series resistance was monitored throughout
experiments using a 5mV step command and cells showing
a 420% change in series resistance, a series of resistance of
420MV or an unstable holding current were rejected.
Recordings of excitatory postsynaptic currents (EPSCs)
were performed in the presence of DL-APV (DL-2-amino-
5-phosphonopentanoic; 100mM), picrotoxin (100 mM) and
CGP55845 (5 mM) to block NMDA-, GABAA- and GABAB-
receptors, respectively. Decanoic acid (Sigma) was added to the
perfusion solution. EPSCs were evoked by stimulation of
Schaffer collaterals. Paired pulses were evoked with stimula-
tions separated by 50ms. Inhibitory postsynaptic current
(IPSCs) were recorded in the presence of DL-APV (100 mM),
NBQX (10 mM) and CGP55845 (5 mM) to block NMDA-,
AMPA- and GABAB-receptors, respectively.
Recordings were obtained using a MultiClamp 700B ampli-
ﬁer (Axon instruments) and ﬁltered at 4 kHz, digitized at
10 kHz, and stored on a PC. LabView8 (National instruments)
was used for data acquisition and off-line analysis.
In vitro RNA transcription of AMPA
receptor subunits
The AMPA receptor (ﬂip isoform) cDNAs inserted in a SP6
polymerase expression vector (pSP6T) were a generous gift
from Prof. Ralf Schoepfer (NPP, UCL). RNA was transcribed
in vitro from MluI linearized transcripts using the SP6
Promega RiboMAX RNA synthesis kit according to manu-
facturer’s protocols except for the addition of 0.75mM
capping nucleotide m7G(5’)ppp(5’)G (Promega) and 1.6mM
GTP. cRNA concentrations and integrity were estimated by
the intensity of ﬂuorescence bands in RNA denaturating gels.
AMPA receptor cRNAs were mixed in a nominal 1:1 ratio and
5 ng was injected per oocyte.
Oocyte preparation and injection
Xenopus laevis oocytes were purchased from the European
Xenopus Resource Centre, University of Portsmouth. Stage V
to VI oocytes were mechanically dissected and then subjected
to gentle shaking for 30–50min at room temperature with
modiﬁed Barth’s solution (in mM): 88 NaCl, 1 KCl, 2.4
NaHCO3, 0.82 MgCl2, 0.77 CaCl2, 15 Tris-Cl, adjusted to
pH 7.4 with NaOH (Sigma-Aldrich), supplemented with
50 IU/ml penicillin and 50 mg/ml streptomycin (Invitrogen)
and 50 mg/ml tetracycline (Sigma-Aldrich) and 1% collagenase
(type 1A). Healthy oocytes were manually defolliculated and
the injections of cRNA for homomeric subunits alone (GluA1),
or heteromeric mixtures of two subunits together (GluA1/
GluA2 or GluA2/GluA3) were made using an automated
Drummond Nanoinject II injector. The oocytes were then
incubated at 17C in modiﬁed Barth’s solution for at least
48 h before use in electrophysiological recordings.
Two-electrode voltage clamp
recordings from oocytes
Experiments were performed at room temperature (21–
23C). An oocyte was placed in a recording chamber (0.3–
0.5ml volume) and perfused with ND96 solution (96mM
NaCl, 2mM KCl, 1.8mM CaCI2, 1mM MgCl2, 5mM
HEPES, with pH adjusted to 7.5). Current and voltage elec-
trodes were ﬁlled with 300mM KCl and made from thin-
walled borosilicate glass (GC150TF-7.5, Harvard Apparatus)
using a PC-10 electrode puller (Narashige Instruments) and
had resistances of 0.5–2M. Oocytes were voltage-clamped
to a holding potential of 50mV or 60mV using a Turbo
TEC-03 ampliﬁer (npi electronics). Compounds were dissolved
in distilled water or DMSO and dissolved in bathing solution
to achieve their ﬁnal concentrations during experiments, and
were applied under gravity ﬂow during the experiment by
using a multi-valve perfusion system (VC3-8C, ALA Scientiﬁc
Instruments). The bath solutions were perfused at a rate of
10ml/min. Recordings were ﬁltered at 20Hz and digitized at
100Hz (Digidata 1322A, Molecular Devices) before recording
to computer hard disk. Data acquisition was performed using
the Windows PC-based program, WinEDR v3.0.6 (John
Dempster, University of Strathclyde, UK).
Molecular dynamics studies
SMILES format of each ligand was converted to 3D PDB ﬁles
using Open Babel (Ver. 2.3.2). The obconformer function
was then used to ﬁnd the lowest energy conformation from
5000 test conformers after 100 geometry optimization steps.
A GluA2 receptor molecule (Protein Data Bank Code 3KG2)
downloaded from the Research Collaboratory for Structural
Bioinformatics Protein Data Bank (RSCB PDB) was processed
using AutoDock (Ver 1.5.6) in which solvent water mol-
ecules, duplicate subunits (B, C, and D), and bound lig-
ands (zinc, b1.5.6) in which solvent water molecules,
FJ1 [7-morpholin-4-yl-2,3-dioxo-6-(triﬂuoromethyl)-3,4-
dihydroquinoxalin-1(2H)-yl]methyl}phosphonic acid)] were
removed. Polar hydrogens were retained after the addition
of Kollman charges and the distribution of charge deﬁcit.
Beginning with the ligand in its lowest energy conformation,
each was then allowed to rotate freely about its single bonds
during the docking process. For 3KG2, the docking grid was
set in a 126-unit box centred at x: 16.971, y: 40.698,
and z: 106.466 with 0.528 A˚ spacing; this encompassed
the entire transmembrane domain of the A subunit
(Supplementary Fig. 6). The docking search parameters used
AutoDock’s Genetic Algorithm with 25 runs of 2.5 million
evaluations and an initial population size of 250. Upon com-
pletion of docking of each ligand, the numbers of conform-
ations as well as the range of their binding energies were
noted for each cluster of docking locations. The amino acid
residues within 6 A˚ of the lowest energy conformation of each
bound ligand were noted. The residues most frequently par-
ticipating in binding with the various ligands were targeted as
the most likely common binding site for 3KG2
(Supplementary Fig. 3).
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Statistical analysis
The data from the electrophysiology experiments were ana-
lysed using GraphPad Prism software and SPSS (IBM) with
IC50 values calculated using y = 100 / (1 + 10(x logIC50)).
Statistical analysis was performed using ANOVA with Tukey
post hoc test, paired t-test or unpaired t-test.
Results
Decanoic acid, not ketones, acutely
inhibits epileptiform activity
We initially assessed whether the acute antiseizure effects of
the MCT ketogenic diet are related to a direct effect of
decanoic acid or ketone bodies (b-hydroxybutyrate and acet-
one). Here we used two different in vitro models of epilepti-
form activity generated by decreasing GABAergic inhibition
(pentylenetetrazol) (Fig. 1A–C) or potentiating NMDA recep-
tor currents (low magnesium) (Fig. 1D–F). In both models,
even at high concentrations (10mM), ketone bodies did not
have any effect on epileptiform activity. In contrast, at a
concentration at which valproic acid, a branched chain
fatty acid and long-established antiepileptic drug, only modi-
ﬁes seizure activity in these models (1mM) (Chang et al.,
2012, 2013), decanoic acid completely blocked epileptiform
activity in both models (Fig. 1). This supports an antiseizure
effect of the decanoic acid component of the MCT diet,
rather than diet-derived ketones.
Decanoic acid acutely inhibits
excitatory postsynaptic currents
We next asked what the molecular mechanisms for the
effect of decanoic acid in seizure control are likely to be.
As most antiepileptic drugs modify synaptic transmission or
neuronal excitability, we ﬁrst tested the effect of decanoic
acid on either excitatory or inhibitory neurotransmission by
determining the effect of decanoic acid on evoked EPSCs
and IPSCs in acute ex vivo hippocampal slices. For these
experiments, we performed whole-cell patch clamp record-
ings from CA1 pyramidal neurons and stimulated the
Figure 1 Decanoic acid but not ketones acutely reduce epileptiform activity in two acute ex vivomodels. Epileptiform activity was
monitored using two ex vivo rat hippocampal slice models, following treatment with decanoic acid (DA, 1 mM) or ketones acetone and b-
hydroxybutyrate (BHB) (both at 10 mM) or with solvent-only (Control). (A) Example trace recording of epileptiform activity (burst discharges) in
hippocampal slices induced by application of pentylenetetrazol (PTZ, 2 mM, K + 6 mM), a model for generalized seizures, and following treatment,
where (B) the frequency of epileptiform activity is plotted against time, following treatment, and also shown as a comparison of the mean (SD)
frequency of burst discharges averaged from 20 to 40 min post-compound addition. (C) Example trace recording of epileptiform activity (burst
discharges) in hippocampal slices induced by low-Mg2 + conditions, as a model for drug-resistant seizures, and following treatment, where (D) the
frequency of epileptiform activity is plotted against time, and also shown as a comparison of the mean (SD) frequency of burst discharges
averaged from 20 to 40 min post-compound addition. Significance indicated by ***P5 0.001 compared to control (ANOVA with Tukey post hoc
test). All data were normalized to baseline. Data are provided from between n = 4 and 7 repeats.
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stratum radiatum in the presence of NMDA-, GABAA- and
GABAB-receptor blockers to isolate AMPA receptor
mediated EPSCs or in the presence of NMDA-, AMPA-
and GABAB-receptor blockers to isolate GABAA receptor
mediated IPSCs and applied 300mM (52 mg/ml) decanoic
acid [similar to peak serum concentration of children on
the MCT diet (Sills et al., 1986a), and to the serum and
brain concentrations necessary for acute seizure effects in
mice (Wlaz et al., 2015)]. Decanoic acid decreased
the EPSC amplitude by 38.9  5.5%, (n = 6; P5 0.001;
Fig. 2A and C), but had no signiﬁcant effect on evoked
IPSCs (Fig. 2B and D). Furthermore, decanoic acid
(300 mM) had no effect on 1/CV2 (CV, coefﬁcient of vari-
ation) for EPSCs (decanoic acid versus baseline; n = 6:
P = 0.95; Fig. 2E) or IPSCs (decanoic acid versus baseline;
n = 6: P = 0.95; Fig. 2F), and did not affect the paired pulse
ratio for EPSCs (decanoic acid versus baseline; n = 6;
P = 0.69 Supplementary Fig. 1A and B), consistent with a
postsynaptic locus of action. At a concentration compar-
able to the steady state of decanoic acid in children on the
MCT diet (100 mM) (Sills et al., 1986a); decanoic acid still
signiﬁcantly reduced EPSC amplitudes by 17.0  5.6%
(P = 0.01; n = 6). Our results are, therefore, consistent
with a signiﬁcant (direct or indirect) effect of decanoic
acid on postsynaptic excitatory (AMPA) receptor activity.
Decanoic acid directly inhibits AMPA
receptor activity
To determine whether decanoic acid has a direct effect on
AMPA receptor activity, we employed a heterologous
Figure 2 The effect of decanoic acid on EPSCs and IPSCs. Currents were recorded from hippocampal CA1 pyramidal cells following
exposure to decanoic acid (DA; 300 mM). (A) Representative electrophysiological recordings show reduced evoked EPSC amplitude following
application of decanoic acid. The insert provides the average of 10 traces from the same cell indicating the shape of single EPSCs before (1), during
(2) and after (3) application of decanoic acid. (B) Representative electrophysiological recordings show no effect of decanoic acid on IPSCs. (C)
Summary data showing the effect of decanoic acid on mean normalized EPSCs  SEM (n = 6). (D) In contrast, decanoic acid had no effect on mean
normalized IPSCs  SEM (n = 6). Decanoic acid did not change 1/CV2 (CV, coefficient of variation) of EPSC (E) or IPSC (F) amplitudes with
means  SEM pre- and post-decanoic acid treatment as indicated, consistent with a post-synaptic locus of action.
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expression system in which AMPA receptor subunits
(GluA2/3) were expressed in Xenopus oocytes and agonist
elicited inward currents were used to test the inhibitory
activity of decanoic acid. In these experiments, we mea-
sured the effect of decanoic acid, octanoic acid and valproic
acid (all at 1mM; n = 12), on currents elicited by applica-
tion of 100mM L-glutamate. In line with its anticonvulsant
efﬁcacy (Chang et al., 2012, 2013), decanoic acid markedly
reduced AMPA receptor currents (32.4  2.0% of control,
n = 24, P5 0.001; Fig. 3A and B), whereas octanoic acid
had no effect. Valproic acid also showed no action on
AMPA receptor currents. Inhibitory dose-response
curves showed that the effect of decanoic acid was dose
dependent (Fig. 3C and D), and more potent (mean
IC50 = 0.52  0.02mM, n = 12) than that of octanoic
acid (mean IC50 = 3.82  0.03mM, n = 10). The inhibition
of glutamate elicited inward currents by decanoic acid was
also seen in oocytes expressing GluA1 homomeric channels
(Fig. 3E and F). Decanoic acid also inhibited AMPA recep-
tors following activation with the selective high-afﬁnity
AMPA receptor agonist, AMPA (30 mM; 16.7  2.7% of
AMPA alone; n = 8; P5 0.001) (Supplementary Fig. 2).
This inhibitory effect indicates a direct, structurally speciﬁc
inhibition of AMPA receptor currents by decanoic acid.
We next investigated if AMPA receptor inhibition could
block epileptiform activity in vitro using the hippocampal/
pentylenetetrazol seizure model. Here we tested whether
GYKI 52466—a non-competitive AMPA receptor antagon-
ist—at a concentration that gives the same degree of AMPA
receptor antagonism as 1mM decanoic acid (Arai, 2001).
Figure 3 The direct effect of decanoic acid on AMPA receptor-mediated currents. In these experiments, Xenopus oocytes were used
to express AMPA (GluA2/A3 or GluA1) receptors, and currents were measured following application of L-glutamate (100 mM) with membrane
potential clamped to 50 mV. (A) Representative trace recordings for GluA2/3, showing the effect of medium chain fatty acids decanoic acid
(DA), octanoic acid (OA) and VPA (all at 1 mM) and the AMPA receptor inhibitor CNQX (30mM) on inward currents; and (B) summary of mean
normalized currents (SEM). (C) Representative current traces of inhibitory dose-response curves for octanoic or decanoic acid. (D) Mean
inhibitory dose-response curves for octanoic or decanoic acid, graphs show means  SEM. (E) Representative trace recordings for GluA1,
showing the effect of medium chain fatty acids and VPA on inward currents. (F) Summary of mean normalized currents (SEM). Statistical analysis
was performed using ANOVA with Dunnett’s post hoc test. *P5 0.05, ***P5 0.001, compared to control; + + +P5 0.001, compared to solvent
only (DMSO). Scale bars = 15 nA for octanoic acid and 5 nA for decanoic acid.
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GYKI 52466 (50 mM) completely blocked in vitro epilepti-
form activity induced by pentylenetetrazol (Fig. 4), indicat-
ing that the AMPA receptor antagonism of decanoic acid is
sufﬁcient to explain its pharmacological effect in vitro.
We have previously observed that chemical modiﬁcation
of medium chain fatty acids can increase their potency
against multiple in vitro and in vivo seizure models
(Chang et al., 2012, 2013, 2014a). For example, although
octanoic acid shows little seizure control in these models, a
branched derivative, 4-methyloctanoic acid is strongly active.
We therefore examined the potency of 4-methyloctanoic acid
for inhibitory activity at AMPA receptors (GluA2/3) (Fig. 5).
This compound showed strong inhibitory activity [IC50
0.84  0.04mM (n = 14)], consistent with that shown for
seizure control. These data are consistent with medium
chain fatty acid derivatives providing direct AMPA receptor
inhibition relating to seizure control.
Decanoic acid inhibition of
AMPA receptor activity is subunit
dependent, non-competitive and
voltage dependent
We next explored the subunit-dependency of decanoic acid
inhibition on AMPA receptors. We employed oocytes
expressing a homomeric (GluA1 subunit), and heteromeric
(GluA1/2 and GluA2/3) AMPA receptors and measured
currents following glutamate treatment (100 mM). Similar
to the previous experiments, decanoic acid had a potent
inhibitory effect on homomeric GluA1 AMPA receptors
(Fig. 6A and B; IC50 = 2.09mM; P5 0.001 compared to
solvent only), whereas octanoic acid and valproic acid
had no effect. Decanoic acid’s potency was greater at
the GluA1/2 heteromeric complex (Fig. 6A and B;
IC50 = 1.16mM; P50.001 compared to GluA1 homo-
mer), and even greater at the GluA2/3 heteromeric complex
(Fig. 6A and B; IC50 = 0.52mM; P5 0.001 compared to
GluA1/2 heteromer). This suggests that decanoic acid is a
broad spectrum AMPA receptor inhibitor, but with differ-
ing potency at speciﬁc subunit combinations.
We further investigated the nature of decanoic acid-
dependent AMPA receptor inhibition. We measured glutam-
ate dose-response curves in the absence and presence of
either 0.3mM or 1mM decanoic acid using GluA2/3
(Fig. 6C and D). Competitive inhibition would be predicted
to shift the dose-response curves to the right (increasing the
EC50 but with the same maximal response). However, in
contrast, we observed a signiﬁcant reduction in mean EC50s
for glutamate in the presence of decanoic acid compared to
control [from 0.029mM for control to 0.015mM and
0.018mM for 0.3mM (P5 0.001) and 1.0mM (P5 0.01)
Figure 5 The effect of 4-ethyloctanoic acid on AMPA (GluA2/A3) mediated current in Xenopus oocytes induced by
L-glutamate. (A) Representative trace recording showing the effect of 4-ethyloctanoic acid at indicated concentrations on AMPA (GluA2/A3)
current following application of glutamate (100 mM). (B) Inhibitory dose-response curves of 4-ethyloctanoic acid (n = 4) in the presence of
glutamate (100 mM), with data present as means  SEM. The responses are normalized to the maximal current response induced by application of
L-glutamate for each recording.
Figure 4 The effect of AMPA receptor antagonism with
GYKI 52466 on epileptiform activity. Epileptiform activity
induced by application of pentylenetetrazol (2 mM, K + 6 mM) was
monitored following treatment with the selective AMPA receptor
antagonist GYKI 52466 at a concentration (50mM) that results in
approximately the same (60–70%) decrease in AMPA receptor
responses ( SD) as is observed with 1 mM decanoic acid (n = 4).
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Figure 6 Characterization of decanoic acid-dependent AMPA receptor inhibition. In these experiments, Xenopus oocytes were used to
express various AMPA receptor combinations, and glutamate-elicited currents were measured in the presence of varying decanoic acid concen-
trations. (A) Representative current trace showing different AMPA receptor subunit combinations (GluA1; GluA1/2; GluA2/3) following exposure to
varying decanoic acid concentrations (0.001, 0.05, 0.3, 0.7, 1 and 3 mM) on current following application of glutamate (at 100mM). Scale bars = 200
nA for GluA1 and GluA1/2; 20 nA for GluA2/3, and (B) mean inhibitory dose-response curves of decanoic acid from different AMPA receptor
combinations (inset provides IC50 values) (n = 12). (C) Representative traces from electrophysiological recordings showing the effect of glutamate
(0.001, 0.003, 0.01, 0.03, 0.1, 0.3 mM) on GluA2/3 currents in the presence of decanoic acid (at 0.3 mM or 1 mM). Scale bar = 5nA (no decanoic acid);
2 nA (0.3 mM decanoic acid); and 4 nA (1.0 mM decanoic acid). (D) Quantitative evaluation of decanoic acid potency against GluA2/3 currents
showing mean glutamate concentration-response curves (n = 5 for each treatment) where responses are normalized to the maximal current for each
recording in the absence of decanoic acid. (E) Representative current trace of the inhibitory dose–response curves for decanoic acid in the presence
of glutamate (100mM; n = 20 and 1 mM; n = 6) for GluA2/3 receptors and (F) mean inhibitory dose–response curves for decanoic acid against GluA2/
3 in the presence of 100mM or 1 mM glutamate show little change, suggesting a non-competitive inhibition of AMPA mediated current with respect to
glutamate. (G) Representative current traces of the voltage dependence of decanoic acid inhibitory activity, where inhibition curves for decanoic acid
in the present of glutamate (100mM) for GluA2/3 receptors with voltage clamped to 80 and 40 mV. Scale bars = 200 nA and 20 nA, respectively.
(H) Mean inhibitory dose-response curves at 80 and 40 mV (inset provides IC50 values) (n = 6).
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decanoic acid, respectively; Fig. 6D] and also a marked re-
duction in the maximal response at increasing decanoic acid
concentrations. Such observations indicate that decanoic
acid displays non-competitive inhibition at AMPA receptors.
Furthermore, we also compared the mean IC50s of decanoic
acid in the presence of low (100mM) and high (1mM)
glutamate concentrations (Fig. 6E and F). Application of
decanoic acid resulted in a concentration-dependent reduc-
tion in the glutamate-induced (100mM) AMPA receptor
current with an IC50 value of 0.52  0.02mM (n = 12;
Fig. 6E and F). Repeating these experiments at higher glu-
tamate concentrations (1mM) did not alter the inhibitory
effect (0.54  0.03mM, n = 10; Fig. 6E and F), suggesting
that decanoic acid inhibition is not reversed by higher glu-
tamate concentrations and is acting as a non-competitive
inhibitor of AMPA receptors. This indicates that decanoic
acid is likely to bind to a different region of AMPA recep-
tors from that to which glutamate binds, and that this in-
hibitory mechanism may be shared amongst a number of
fatty acids with anti-seizure activity.
We then investigated the voltage-dependence of
direct AMPA receptor inhibition by decanoic acid using
GluA2/3. Here, we clamped the voltage across the oocyte
membrane at different membrane potentials, and
examined changes in inhibitory activity of decanoic acid
on AMPA-dependent current that may occur during synap-
tic depolarization. In these experiments, decanoic acid
shows enhanced AMPA inhibition at the more depolarized
membrane potential, 40mV, where the IC50 is
0.43  0.09mM (n = 6) in comparison to 80mV, where
the IC50 is 1.11  0.05mM (n = 6) (Fig. 6G and H).
Decanoic acid binds in the channel of
AMPA receptors
We next sought to identify a potential binding site for
decanoic acid within the AMPA receptor using a modelling
approach with the AMPA-sensitive, homotetrameric, rat
GluA2 receptor (3KG2). In silico analysis was used to
evaluate the binding of both decanoic acid and perampanel
in the transmembrane domain of 3KG2 (Morris et al.,
2009), where over 2.5 million conﬁrmations of decanoic
acid and 3KG2 were evaluated, and the 25 conformations
producing the lowest binding energy were used to deﬁne
speciﬁc binding locations within the receptor. From these,
the frequency of individual amino acid residues participat-
ing in binding (i.e. within 6 A˚ of decanoic acid) were deter-
mined (Supplementary Fig. 3). The most frequent residues
involved in binding decanoic acid span residues 584–590
(Fig. 7A and B) (Supplementary Fig. 3). This coincides with
the M3 helix of the transmembrane domain and, speciﬁc-
ally, those residues found to inﬂuence the inward current
through the receptor and thought to be involved in gating.
We also examined the site for perampanel, a recently intro-
duced treatment for partial onset seizures and showing ef-
ﬁcacy in drug resistant epilepsy (Russo et al., 2012; Rektor,
2013). Our modelling approach predicted perampanel to
bind to a region in the border between S1 and the channel,
consistent with that identiﬁed in other reports (Szenasi
et al., 2008; Rogawski, 2011). These data suggest that
decanoic acid binds directly to the AMPA receptor channel,
at a location separate from that of perampanel, and thus
may exhibit a different physiological effect to perampanel.
Figure 7 Decanoic acid binding of AMPA receptors. A molecular modelling approach was taken to investigate binding sites of decanoic
acid on AMPA receptors using the active protein configuration (3KG2) of GluA2 and modelling residues within 6 A˚ of the ligand. (A) Decanoic
acid is predicted to bind within the channel region of the receptor (magenta) on the M3 helices (overall structure shown in inset). Using this
modelling approach, the known AMPA receptor agonist, perampanel, is predicted to bind to the linker region between the S1 glutamate binding
domain and the channel pore (blue). (B) View from the intracellular side down the axis of the ion channel pore. Space-filled molecule is decanoic
acid (magenta carbons and two red carboxylic acid oxygen molecules) binding at Pro584 (green) of one subunit with the equivalent binding of
decanoic acid at the other three subunits omitted for clarity.
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Discussion
The predominant mechanism of ketogenic diets, as the
name suggests, has been widely considered to be through
the production of ketone bodies (Bough and Rho, 2007;
Rho and Stafstrom, 2011), such as 3-hydroxybutyrate and
acetoacetate, since these are found to be elevated in the
plasma of patients on the diet (Huttenlocher, 1976).
However, a correlation between blood ketone levels and
seizure control in patients and animal models has not
been consistently found (Thavendiranathan et al., 2000).
Our study suggests that decanoic acid, rather than ketones,
may provide the direct molecular mechanism of MCT keto-
genic diet, in two ex vivo models for drug-resistant epi-
lepsy, although ketones are likely to provide other
beneﬁts (Bough and Rho, 2007; Rho and Sankar 2008;
Rho and Stafstrom, 2011; Kim et al., 2015). This is further
supported by other studies showing that ketone bodies do
not directly alter excitatory or inhibitory hippocampal syn-
aptic transmission (Thio et al., 2000) nor affect epilepti-
form activity (either interictal or ictal activity) induced by
4-aminopyridine in hippocampal-entorhinal cortex slices
(Thio et al., 2000), although ketones have been shown to
modulate vesicular glutamate transporter activity at pre-
synaptic sites (Juge et al., 2010). Nevertheless, there may
be circumstances, when ketones do play a greater role such
as in Glut1 deﬁciency, in which ketones from the ketogenic
diet provide the brain with an alternative energy source
(Veggiotti and De Giorgis, 2014). Moreover, the ketogenic
diet in the longer term may modify metabolic and gene
expression, which could have important disease-modifying
effects (Masino et al., 2011; Kim et al., 2015). Also, the
ketogenic diet (with reduced glucose) decreases cellular
pyruvate/oxaloacetate concentrations, which has recently
been shown to hyperpolarize neurons through an effect
on neuronal potassium currents (Sada et al., 2015).
The classical (long chain triglyceride; LCT) ketogenic
diet, which has been shown to be as effective as the
MCT diet (Neal et al., 2009), provides up to 90% of the
calories in the diet as fat and is extremely restrictive. In
contrast, the MCT diet allows less energy to be provided
as total fat (typically resulting in a total fat intake of
65–75% energy) allowing for a less restrictive and more
varied diet. The implication of our results for the mechan-
ism of action for the classical diet are yet to be explored;
however, long chain fats are metabolized to shorter chain
fats and it would thus be expected that serum medium
chain fats will be increased. Future studies to monitor
brain medium fatty acid levels in animal models and in
patient plasma during ketogenic diets will be necessary to
determine the role of fatty acids in the control of seizures.
Decanoic acid is a major constituent of the MCT keto-
genic diet, providing 40% of the medium chain fat within
the diet (Sills et al., 1986a). Even though decanoic acid is
extensively metabolized to carbon dioxide, ketone bodies,
and long chain fatty acids, it has been reported that there
are high concentrations of decanoic acid (averaging
156.7 mM) in the serum of children with intractable epi-
lepsy treated with MCT diet for the control of drug-resist-
ant seizures (Haidukewych et al., 1982; Sills et al., 1986a;
Dean et al., 1989). A direct correlation between decanoic
acid concentrations and seizure control has not, however,
been shown, partly because the studies are too small to
demonstrate such a correlation, but also because the keto-
genic diet may have multiple other actions. Importantly,
mice treated with decanoic acid by gastric gavage
(30mmol/kg; Wlaz et al., 2012) have increased brain
decanoic acid concentrations (up to 240mM), which repre-
sent 60–80% of serum levels. These results indicate that
fatty acids are present in appreciable amounts in the per-
ipheral blood and brain and therefore are ideally placed to
have an effect on seizure control in the brain. Decanoic
acid has also been shown to delay the onset of picro-
toxin-induced clonic seizures and prolong the survival
time in mice with pentylenetetrazol-induced convulsions
(Nakamura et al., 1990). In addition, there is a direct
effect of the fatty acids contained in MCT on cerebral ex-
citability (Huttenlocher et al., 1971; Sills et al., 1986a, b).
As we also show that decanoic acid inhibits epileptiform
activity in vitro, it is likely that decanoic acid is a signiﬁ-
cant therapeutic component of the diet.
We determined the acute effect of decanoic acid on syn-
aptic transmission in the CA1 area of the rat hippocampus
and identiﬁed that decanoic acid reduced EPSC amplitude,
at a similar concentration to peak plasma concentrations in
children undergoing the diet (300 mM; Haidukewych et al.,
1982; Sills et al., 1986a; Dean et al., 1989) and in a
manner consistent with a postsynaptic effect. Moreover,
the same concentration of decanoic acid had no appreciable
effect on inhibitory transmission. These data indicate that
decanoic acid acts at AMPA receptors. These receptors pro-
vide a recognized target for seizure control, and mediate
fast glutamatergic synaptic transmission in the CNS
(Traynelis et al., 2010; Rogawski, 2011). AMPA receptors
play a key role in generating and propagating epileptic ac-
tivity and, in the long-term, adaptive cellular plasticity
associated with epileptogenesis (Rogawski and Donevan,
1999; Chapman, 2000). The receptors are present in all
areas of the brain relevant to epilepsy, including the cere-
bral cortex, amygdala, thalamus and hippocampus
(Beneyto and Meador-Woodruff, 2004; Rogawski, 2011).
Furthermore, AMPA receptor antagonists have a broad
spectrum of anticonvulsant activity in various in vitro
and in vivo epilepsy models (Rogawski and Donevan,
1999; Rogawski, 2011). Here we show that the degree of
AMPA receptor antagonism by decanoic acid is sufﬁcient
to explain its antiseizure effect. Similarly, perampanel, a
recently approved treatment for refractory partial epilepsy,
acts through AMPA receptor antagonism (Rektor, 2013).
Thus, our results showing that decanoic acid reduces the
magnitude of fast glutamatergic signalling in the hippocam-
pus are consistent with previous reports that AMPA recep-
tors are a recognized target for antiseizure therapies
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(Meldrum and Rogawski, 2007; Szenasi et al., 2008; Russo
et al., 2012).
The results from ex vivo hippocampal slices do not, how-
ever, distinguish a direct from an indirect effect of decanoic
acid on AMPA receptors. To overcome this, we used a heter-
ologous expression model, where AMPA receptors were
expressed in Xenopus oocytes to enable a detailed charac-
terization of the effect of decanoic acid on AMPA receptor
activity. Decanoic acid directly inhibited AMPA receptors
comprised of GluA1 homodimers, and GluA1/2 and
GluA2/3 heterodimers—the latter two represent the two
most abundant AMPA receptor combinations in the adult
brain (Santos et al., 2009; Wang et al., 2012). It is interest-
ing to note that patients with chronic epilepsy show a sig-
niﬁcant increase of hippocampal dendritic GluA2/3 subunits
in dentate granule cells (de Lanerolle et al., 1989), and our
data would suggest a concomitant enhanced efﬁcacy of
decanoic acid in this population. GluA subunits show differ-
ential spatial and temporal changes in subunit expression
throughout development (Talos et al., 2006), and the
GluA2/3 subunits are expressed at increased levels during
postnatal development (postnatal Days 10–15) in the rat
hippocampus (Arai et al., 1997), and long-term expression
changes following the development of epilepsy in animal
models (Friedman et al., 1994). These results indicate that
decanoic acid exerts a direct effect on AMPA-mediated cur-
rents, at concentrations as low as 100mM (providing 20%
inhibition), suggesting a likely inﬂuence on neuronal function
in patients on the MCT ketogenic diet. However, the ﬁnding
that decanoic acid likely has additional therapeutic targets
due to its effect on phosphoinositides (Chang et al., 2012,
2014a, b), raises the question of whether this degree of
AMPA receptor antagonism is sufﬁcient to explain its thera-
peutic effects in humans. Perampanel, a selective AMPA re-
ceptor antagonist, at the free concentrations observed to be
efﬁcacious in humans, 30–50nM (Rogawski and Hanada,
2013), results in 20% reduction in ﬁeld EPSP slope
(Ceolin et al., 2012). This effect is of a similar magnitude
to the effect that we observed with therapeutically relevant
concentrations of decanoic acid, indicating that the AMPA
receptor antagonism may be sufﬁcient to explain the antisei-
zure effects in humans (although we cannot exclude that its’
effect on other targets could also play a part).
We continued our investigation into AMPA receptor in-
hibition by further characterizing the mechanism of
decanoic acid inhibition, in particular determining whether
it competes with glutamate for binding to the AMPA re-
ceptor. This is relevant as during conditions in which there
are large rises in glutamate concentrations (such as seizure
activity), competitive inhibitors may be less effective.
However, we clearly demonstrate that varying the glutam-
ate concentration by an order of magnitude does not alter
the IC50 of decanoic acid inhibition, indicating that
decanoic acid is a non-competitive inhibitor at AMPA re-
ceptors. The potency of decanoic acid-dependent AMPA
receptor inhibition is therefore independent of increased
glutamate during seizure activity and will still occur at
synaptic glutamate concentrations in the millimolar range
(Clements et al., 1992). We also determined that AMPA
receptor inhibition by decanoic acid is voltage-dependent,
and is more effective at depolarized potentials. This voltage
dependence suggests that the therapeutic effect of decanoic
acid in reducing AMPA receptor currents is enhanced
during post-synaptic activation and seizure propagation.
This result also suggests that the binding site for decanoic
acid lies in or near to the channel region of the receptor
and is consistent with the properties of known AMPA re-
ceptor pore blockers such as the polyamines (Washburn
and Dingledine, 1996).
Our modelling of the binding of decanoic acid to AMPA
receptors also suggests a binding site in the channel region
of the receptor. Our data indicate that decanoic acid binds
by means of hydrogen bonding between its two carboxylic
acid oxygens and the two hydrogens of the cyclic amine
group of proline at residue position 584 on each of the four
M3 helices subunits within the ion channel. It is likely that
the binding of decanoic acid to each of the four subunits
cooperatively contributes to its therapeutic effects. We be-
lieve that this mode of action will provide both steric effects
restricting the physical dimensions of the ion channel pore
coupled to electrostatic interactions between the negatively
charged carboxylic group and cations ﬂowing through the
ion channel. Interactions between decanoic acid and cations
passing through the channel would not only result in fur-
ther narrowing the ion channel pore, but also create a posi-
tive electrostatic ﬁeld which may serve to repel and prevent
additional cations from passing through the blocked ion
channel. However, the precise mechanistic aspects of
decanoic acid function, including possible effect on receptor
desensitization, remain unclear. The distinct localization of
binding for decanoic acid and perampanel (Szenasi et al.,
2008; Rogawski, 2011) suggests different inhibitory proﬁles
and, possibly, clinical effects. This may explain why certain
adverse effects of perampanel, such as increased aggression
(Rugg-Gunn, 2014; Steinhoff et al., 2014), are not so evi-
dent with the MCT ketogenic diet. Moreover, as perampa-
nel and decanoic acid act at separate sites, it is possible that
they have a cooperative effect at the AMPA receptor, sug-
gesting that permapanel and the ketogenic diet could be
synergistic.
Our results have far-reaching clinical implications. For
Lennox-Gastaut syndrome, Doose syndrome and Dravet’s
syndrome antiepileptic drugs are often insufﬁcient to obtain
seizure control and non-pharmacological interventions are
often required. Here the MCT diet can be effective in seiz-
ure management (Kossoff and Rho, 2009; Vanstraten and
Ng, 2012; Laux and Blackford, 2013), and enhanced diet-
ary intake of decanoic acid may provide additional thera-
peutic beneﬁt. Furthermore, treatment of adults with
drug-resistant epilepsy, who show poor compliance to the
stringent dietary regimen necessary for the MCT diet, may
better tolerate a normal diet with just added decanoic acid,
e.g. in the form of a triglyceride.
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There are a range of limitations to the discovery of an
acute effect of decanoic acid on seizure control. First, it is
likely that decanoic acid also has chronic effects, as has
been shown recently on mitochondrial proliferation
(Hughes et al., 2014), and these effects may also have
roles in decanoic acid’s therapeutic function. In addition,
the role of metabolism on elevated blood levels of decanoic
acid (Rho and Sankar, 2008; Rho and Stafstrom, 2011)
remains unclear. Is a reduction in carbohydrate load neces-
sary for elevated blood decanoic acid levels? Recent studies
have suggested that dietary MCT oil, concomitant with a
non-restricted carbohydrate diet, gave rise to ketosis
(Courchesne-Loyer et al., 2013), although changes in spe-
ciﬁc medium chain fatty acids in the plasma were not deter-
mined. Future studies monitoring decanoic acid in the
plasma of patients or healthy individuals on different com-
position MCT oils, or with differing carbohydrate intakes,
should provide indications of the dietary conditions neces-
sary to elevate plasma decanoic acid levels to provide seiz-
ure protection through direct AMPA receptor inhibition.
The direct effect of decanoic acid on AMPA receptor
mediated currents raises a concern of a detrimental effect
on cognitive function. Numerous studies have demon-
strated that AMPA receptors contribute to synaptic
strengthening during long-term potentiation, a cellular
model of synaptic plasticity, and experience-dependent
neuronal plasticity (Talos et al., 2006; Santos et al.,
2009; Wang et al., 2012). This is further supported by
mouse models, lacking the gene encoding the GluA1 sub-
unit (Gria1) exhibiting impaired hippocampus-dependent
memory (Sanderson et al., 2008). However, neither com-
petitive nor non-competitive antagonists of AMPA recep-
tors (at concentrations that inhibit seizure activity) had an
effect on long-term potentiation (a cellular correlate of
learning and memory) (Sanderson et al., 2008), and this
is consistent with in vivo data in which AMPA receptor
antagonists at therapeutic doses do not affect cognition
(Pan et al., 2010). Indeed, in humans, the MCT ketogenic
diet has been shown to have diverse positive effects on
brain function, such as increased alertness, better cognitive
functioning, and improved behaviour, not only in epilepsy
patients (Kinsman et al., 1992; Pulsifer et al., 2001) but
also in patients with type 1 diabetes given an insulin infu-
sion (Page et al., 2009). The extent to which these effects
can be attributed to decanoic acid or other components of
the diet remains to be determined.
Funding
We gratefully acknowledge an NC3Rs grant G0900775 to
R.S.B.W. and M.W. to support this research, and PhD
studentship to K.A. by Vitaﬂo Ltd. P.E.C. is grateful for
funding from the Royal Society. Part of this work was
undertaken at UCLH/UCL which receives a proportion of
funding from the Department of Health’s NIHR Biomedical
Research Centers funding scheme.
Supplementary material
Supplementary material is available at Brain online.
References
Arai AC. GYKI 52466 has positive modulatory effects on AMPA
receptors. Brain Res 2001; 892: 396–400.
Arai Y, Mizuguchi M, Takashima S. Developmental changes of glu-
tamate receptors in the rat cerebral cortex and hippocampus. Anat
Embryol (Berl) 1997; 195: 65–70.
Beneyto M, Meador-Woodruff JH. Expression of transcripts encoding
AMPA receptor subunits and associated postsynaptic proteins in the
macaque brain. J Comp Neurol 2004; 468: 530–54.
Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet.
Epilepsia 2007; 48: 43–58.
Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D,
Volianskis A. A novel anti-epileptic agent, perampanel, selectively
inhibits AMPA receptor-mediated synaptic transmission in the
hippocampus. Neurochem Int 2012; 61: 517–22.
Chang P, Orabi B, Deranieh RM, Dham M, Hoeller O, Shimshoni JA,
et al. The antiepileptic drug valproic acid and other medium-chain
fatty acids acutely reduce phosphoinositide levels independently of
inositol in Dictyostelium. Dis Model Mech 2012; 5: 115–24.
Chang P, Terbach N, Plant N, Chen PE, Walker MC, Williams RS.
Seizure control by ketogenic diet-associated medium chain fatty
acids. Neuropharmacology 2013; 69: 105–14.
Chang P, Walker MC, Williams RS. Seizure-induced reduction in PIP3
levels contributes to seizure-activity and is rescued by valproic acid.
Neurobiol Dis 2014a; 62: 296–306.
Chang P, Zuckermann A, Williams S, Close AJ, Cano-Jaimez M,
McEvoy JP, et al. Seizure control by derivatives of medium chain
fatty acids associated with the ketogenic diet show novel branching-
point structure for enhanced potency. J Pharmacol Exp Ther 2014b;
352: 43–52.
Chapman AG. Glutamate and epilepsy. J Nutr 2000; 130: 1043S–5S.
Clements JD, Lester RA, Tong G, Jahr CE, Westbrook GL. The time
course of glutamate in the synaptic cleft. Science 1992; 258:
1498–501.
Courchesne-Loyer A, Fortier M, Tremblay-Mercier J, Chouinard-
Watkins R, Roy M, Nugent S, et al. Stimulation of mild, sustained
ketonemia by medium-chain triacylglycerols in healthy humans: esti-
mated potential contribution to brain energy metabolism. Nutrition
2013; 29: 635–40.
de Lanerolle NC, Kim JH, Robbins RJ, Spencer DD. Hippocampal
interneuron loss and plasticity in human temporal lobe epilepsy.
Brain Res 1989; 495: 387–95.
Dean HG, Bonser JC, Gent JP. HPLC analysis of brain and plasma for
octanoic and decanoic acids. Clin Chem 1989; 35: 1945–8.
Friedman LK, Pellegrini-Giampietro DE, Sperber EF, Bennett MV,
Moshe SL, Zukin RS. Kainate-induced status epilepticus alters glu-
tamate and GABAA receptor gene expression in adult rat hippocam-
pus: an in situ hybridization study. J Neurosci 1994; 14: 2697–707.
Haidukewych D, Forsythe WI, Sills M. Monitoring octanoic and
decanoic acids in plasma from children with intractable epilepsy
treated with medium-chain triglyceride diet. Clin Chem 1982; 28:
642–5.
Hughes SD, Kanabus M, Anderson G, Hargreaves IP, Rutherford T,
O’Donnell M, et al. The ketogenic diet component decanoic acid
increases mitochondrial citrate synthase and complex I activity in
neuronal cells. J Neurochem 2014; 129: 426–33.
Huttenlocher PR. Ketonemia and seizures: metabolic and anticonvul-
sant effects of two ketogenic diets in childhood epilepsy. Pediatr Res
1976; 10: 536–40.
442 | BRAIN 2016: 139; 431–443 P. Chang et al.
 by guest on M
arch 3, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
Huttenlocher PR, Wilbourn AJ, Signore JM. Medium-chain triglycer-
ides as a therapy for intractable childhood epilepsy. Neurology
1971; 21: 1097–103.
Juge N, Gray JA, Omote H, Miyaji T, Inoue T, Hara C, et al.
Metabolic control of vesicular glutamate transport and release.
Neuron 2010; 68: 99–112.
Kim DY, Simeone KA, Simeone TA, Pandya JD, Wilke JC, Ahn Y,
et al. Ketone bodies mediate anti-seizure effects through mitochon-
drial permeability transition. Ann Neurol 2015; 78: 77–87.
Kinsman SL, Vining EP, Quaskey SA, Mellits D, Freeman JM. Efﬁcacy
of the ketogenic diet for intractable seizure disorders: review of 58
cases. Epilepsia 1992; 33: 1132–6.
Kossoff EH, Rho JM. Ketogenic diets: evidence for short- and long-
term efﬁcacy. Neurotherapeutics 2009; 6: 406–14.
Laux L, Blackford R. The ketogenic diet in Dravet syndrome. J Child
Neurol 2013; 28: 1041–4.
Levy RG, Cooper PN, Giri P. Ketogenic diet and other dietary treat-
ments for epilepsy. Cochrane Database Syst Rev 2012; 3:
CD001903.
Likhodii SS, Musa K, Mendonca A, Dell C, Burnham WM, Cunnane
SC. Dietary fat, ketosis, and seizure resistance in rats on the keto-
genic diet. Epilepsia 2000; 41: 1400–10.
Liu YM. Medium-chain triglyceride (MCT) ketogenic therapy.
Epilepsia 2008; 49 Suppl 8: 33–6.
Masino SA, Li T, Theoﬁlas P, Sandau US, Ruskin DN, Fredholm BB,
et al. A ketogenic diet suppresses seizures in mice through adenosine
A(1) receptors. J Clin Invest 2011; 121: 2679–83.
Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug
development. Neurotherapeutics 2007; 4: 18–61.
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell
DS, et al. AutoDock4 and AutoDockTools4: Automated docking
with selective receptor ﬂexibility. J Comput Chem 2009; 30:
2785–91.
Nakamura J, Miwa T, Sasaki H, Shibasaki J, Kaneto H. Effect of
straight chain fatty acids on seizures induced by picrotoxin and
pentylenetetrazole in mice. J Pharmacobiodyn 1990; 13: 76–81.
Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N,
Fitzsimmons G, et al. A randomized trial of classical and medium-
chain triglyceride ketogenic diets in the treatment of childhood epi-
lepsy. Epilepsia 2009; 50: 1109–17.
Neal EG, Cross JH. Efﬁcacy of dietary treatments for epilepsy. J Hum
Nutr Diet 2010; 23: 113–19.
Oldendorf WH. Carrier-mediated blood-brain barrier transport of
short-chain monocarboxylic organic acids. Am J Physiol 1973;
224: 1450–3.
Page KA, Williamson A, Yu N, McNay EC, Dzuira J, McCrimmon
RJ, et al. Medium-chain fatty acids improve cognitive function in
intensively treated type 1 diabetic patients and support in vitro syn-
aptic transmission during acute hypoglycemia. Diabetes 2009; 58:
1237–44.
Pan Y, Larson B, Araujo JA, Lau W, de Rivera C, Santana R, et al.
Dietary supplementation with medium-chain TAG has long-lasting
cognition-enhancing effects in aged dogs. Br J Nutr 2010; 103:
1746–54.
Pulsifer MB, Gordon JM, Brandt J, Vining EP, Freeman JM. Effects of
ketogenic diet on development and behavior: preliminary report of a
prospective study. Dev Med Child Neurol 2001; 43: 301–6.
Rektor I. Perampanel, a novel, non-competitive, selective AMPA recep-
tor antagonist as adjunctive therapy for treatment-resistant partial-
onset seizures. Expert Opin Pharmacother 2013; 14: 225–35.
Rho JM, Sankar R. The ketogenic diet in a pill: is this possible?
Epilepsia 2008; 49 (Suppl 8): 127–33.
Rho JM, Stafstrom CE. The ketogenic diet: What has science taught
us? Epilepsy Res 2011; 100: 203–346.
Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug
target. Epilepsy Curr 2011; 11: 56–63.
Rogawski MA, Donevan SD. AMPA receptors in epilepsy and as
targets for antiepileptic drugs. Adv Neurol 1999; 79: 947–63.
Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a
selective non-competitive AMPA receptor antagonist. Acta Neurol
Scand Suppl 2013; 19–24.
Rugg-Gunn F. Adverse effects and safety proﬁle of perampanel: a
review of pooled data. Epilepsia 2014; 55 (Suppl 1): 13–15.
Russo E, Gitto R, Citraro R, Chimirri A, De SG. New AMPA antag-
onists in epilepsy. Expert Opin Investig Drugs 2012; 21: 1371–89.
Sada N, Lee S, Katsu T, Otsuki T, Inoue T. Epilepsy treatment.
Targeting LDH enzymes with a stiripentol analog to treat epilepsy.
Science 2015; 347: 1362–7.
Sanderson DJ, Good MA, Seeburg PH, Sprengel R, Rawlins JN,
Bannerman DM. The role of the GluR-A (GluR1) AMPA receptor
subunit in learning and memory. Prog Brain Res 2008; 169: 159–78.
Santos SD, Carvalho AL, Caldeira MV, Duarte CB. Regulation of
AMPA receptors and synaptic plasticity. Neuroscience 2009; 158:
105–25.
Sills MA, Forsythe WI, Haidukewych D. Role of octanoic and
decanoic acids in the control of seizures. Arch Dis Child 1986a;
61: 1173–7.
Sills MA, Forsythe WI, Haidukewych D, MacDonald A, Robinson M.
The medium chain triglyceride diet and intractable epilepsy. Arch
Dis Child 1986b; 61: 1168–72.
Steinhoff BJ, Hamer H, Trinka E, Schulze-Bonhage A, Bien C,
Mayer T, et al. A multicenter survey of clinical experiences with
perampanel in real life in Germany and Austria. Epilepsy Res 2014;
108: 986–8.
Szenasi G, Vegh M, Szabo G, Kertesz S, Kapus G, Albert M, et al. 2,3-
benzodiazepine-type AMPA receptor antagonists and their neuro-
protective effects. Neurochem Int 2008; 52: 166–83.
Talos DM, Follett PL, Folkerth RD, Folkerth RD, Follett PL, Volpe JJ,
et al. Developmental regulation of alpha-amino-3-hydroxy-5-methyl-
4-isoxazole-propionic acid receptor subunit expression in forebrain
and relationship to regional susceptibility to hypoxic/ischemic injury.
II. Human cerebral white matter and cortex. J Comp Neurol 2006;
497: 61–77.
Thavendiranathan P, Mendonca A, Dell C, Likhodii SS, Musa K,
Iracleous C, et al. The MCT ketogenic diet: effects on animal seizure
models. Exp Neurol 2000; 161: 696–703.
Thio LL, Wong M, Yamada KA. Ketone bodies do not directly alter
excitatory or inhibitory hippocampal synaptic transmission.
Neurology 2000; 54: 325–31.
Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM,
Ogden KK, et al. Glutamate receptor ion channels: structure, regu-
lation, and function. Pharmacol Rev 2010; 62: 405–96.
Vanstraten AF, Ng YT. Update on the management of Lennox-
Gastaut syndrome. Pediatr Neurol 2012; 47: 153–61.
Veggiotti P, De Giorgis, V. Dietary treatments and new therapeutic
perspective in GLUT1 deﬁciency syndrome. Curr Treat Options
Neurol 2014; 16: 291.
Wang G, Gilbert J, Man HY. AMPA receptor trafﬁcking in homeo-
static synaptic plasticity: functional molecules and signaling cas-
cades. Neural Plast 2012; 2012: 825364.
Washburn MS, Dingledine R. Block of alpha-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA) receptors by polya-
mines and polyamine toxins. J Pharmacol Exp Ther 1996; 278:
669–78.
Wlaz P, Socala K, Nieoczym D, Luszczki JJ, Zarnowska I, Zarnowski
T, et al. Anticonvulsant proﬁle of caprylic acid, a main constituent
of the medium-chain triglyceride (MCT) ketogenic diet, in mice.
Neuropharmacology 2012; 62: 1882–9.
Wlaz P, Socala K, Nieoczym D, Z_ arnowski T, Z_ arnowska I,
Czuczwar SJ, et al. Acute anticonvulsant effects of capric acid in
seizure tests in mice. Prog Neuropsychopharmacol Biol Psychiatry
2015; 57: 110–16.
Xu X, Muller-Taubenberger A, Adley KE, Pawolleck N, Lee VW,
Wiedemann C, et al. Attenuation of phospholipid signaling provides
a novel mechanism for the action of valproic acid. Eukaryot Cell
2007; 6: 899–906.
Decanoic acid: an AMPA receptor antagonist BRAIN 2016: 139; 431–443 | 443
 by guest on M
arch 3, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
